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Background
HIV-1 utilizes multiple mechanisms to evade immune
surveillance. This has hindered the development of an
effective vaccine. The CD4bs represents a highly con-
served vulnerable site on HIV envelope that serves as an
important target in HIV vaccine development. Novel
concepts, such as resurfacing and glycan masking are
some of the current approaches used to refocus the
immune responses.
Methods
In this study, we used structural information of HIV
gp120 core, together with the computer-assisted protein
design tool to strategically add various glycosylation
sites on the protein surface and create a panel of resur-
faced stabilized core (RSC3)-based derivatives. The mod-
ified proteins were expressed in 293F or GnTi(-/-) cells
and purified by Nickel-affinity and gel-filtration chroma-
tography. To verify the glycosylation sites and antigenic
analysis, the purified proteins were subject to mass spec-
trometry and SDS PAGE analysis using a panel of well-
defined monoclonal antibodies. The proteins with desir-
able antigenicity and well-tolerated glycan additions
were tested for their immunogenicity in mice and NHPs.
Results
Two hyperglycosylated mutants containing five or six
extra glycans (RS3.Y5 and RSC3. Y6.1) elicited CD4bs
antibodies in significant quantities. Variant Y6.1 was
further tested in the NHP model, in which Y6.1 elicited
non-neutralizing CD4bs antibodies. In addition, a novel
glycan mutant Y8.2_1 was developed based on Y6.1
by incorporating 3 extra glycans. Antigenic analysis
indicated that the protein was able to eliminate the
binding of non-neutralizing or less potent CD4bs anti-
bodies such as b12 and b13, but still retain the binding
capacities to potent CD4bs antibodies such as VRC01
and VRC-PG04.
Conclusion
It is now feasible to induce CD4bs antibodies by vaccina-
tion with immunogens that have exogenous N-linked gly-
cans added to mask the “undesired” regions of the
immunogen and have an exposed surface that targets the
CD4bs epitope. Further optimization will be necessary to
obtain CD4bs antibodies with neutralizing activity.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-P23
Cite this article as: Dai et al.: Hyperglycosylated resurfaced stabilized
GP120 core as an immunogen elicits antibodies targeted at the CD4-
binding site. Retrovirology 2012 9(Suppl 2):P23.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Dai et al. Retrovirology 2012, 9(Suppl 2):P23
http://www.retrovirology.com/content/9/S2/P23
© 2012 Dai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
